A pair of trial results published in medical journals suggest switching from high-dose injectables to lower doses or pills could help people with obesity keep their weight down over the long term.

Marty Makary's resignation leaves the agency with temporary directors in three top positions, and a number of newly ...

Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?

Assertio’s latest offer represents a roughly 31% premium over an initial acquisition proposal. Elsewhere, Kyverna is readying a first-of-its-kind approval application and AC Immune is swapping CEOs.

Cell and gene therapies aren’t limited by ideas—they’re limited by where they’re built. See how “ready-now” locations change ...

Makary’s exit ends a turbulent run marred by leadership upheaval, mass layoffs, political pressure and public spats with ...

It’s easy to assume that more data = better models = faster identification. With AI, you can extract associations between ...

Roche has agreed to acquire PathAI, a Boston-based digital pathology firm, for up to $1.05 billion. Roche plans to pay $750 ...

The marketing deal is the latest in a series of recent pacts between GSK and China-based drug companies, and could speed ...

After withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new ...

Inhibrx, the subject of recent buyout rumors, showed its drug might enhance the effects of Keytruda. Elsewhere, Capricor sued its cell therapy partner and Argenx got a revenue boost.

The acquisition hands the Italian pharma a group of medicines approved to treat various CNS disorders and gives it wider ...